Abstract Details

Title Real-world Healthcare Resource Utilization Following Initiation of Subcutaneous IgPro20 Among U.S. Patients With Chronic Inflammatory Demyelinating Polyneuropathy

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P7 - Poster Session 7 (8:00 AM-9:00 AM)

Poster/Presentation
Number 9-017

Objective Characterize HCRU among CIDP patients who initiate subcutaneous IgPro20 (Immune Globulin [Human], 20% Liquid).

Background Intravenous immunoglobulin (IVIg) therapy, during the maintenance phase of chronic inflammatory demyelinating polyneuropathy (CIDP) management, requires infusions in a health care setting. Subcutaneous immunoglobulins (SCIg) can be self-administered at home, increasing patient autonomy. However, the impact of IgPro20 initiation on healthcare resource utilization (HCRU) has not been characterized in a US real-world setting.

Design/Methods This retrospective cohort study used Optum’s de-identified Clinformatics® Data Mart Database (study period: 01/2014 - 12/2024). Adult patients with ≥ 2 CIDP diagnosis claims and ≥ 6 months of enrollment pre and post index entered the cohort upon IgPro20 initiation (index date). Rates per person per year (PPPY) of inpatient (IP), emergency department (ED), and outpatient (OP) claims were evaluated in the 6-month pre-index and 6-month post-index periods.

Results

CIDP patients meeting eligibility criteria (n=207) were 60 years old (median) and male (54%). Following IgPro20 initiation, all-cause IP claims decreased from 0.52 PPPY (SD 1.43) to 0.42 PPPY (SD 1.60); ED claims decreased from 1.00 (SD 2.15) to 0.85 PPPY (SD 2.44).

Post IgPro20 initiation, all-cause OP claims increased from 60.62 (SD 41.62) to 78.33 (SD 41.98) PPPY, largely attributable to IgPro20-related claims and administrative services, especially nursing/home care visits for self-administration training during the first month. Thereafter, all-cause OP claims PPPY decreased from month 1 to month 6 post-index, eventually reaching 67.43 (SD 44.70) PPPY during the 6^th month. All other OP HCRU metrics (e.g, OP claims unrelated to IgPro20/training) decreased post-index.

Conclusions IgPro20 demonstrated a favorable profile in the management of CIDP, with care shifting away from IP and ED settings toward OP. After self-administration training in month one, findings highlight reduced healthcare burden over a longer horizon.

Authors/Disclosures
Patty Riley, RN (CSL Behring) PRESENTER	No disclosure on file
Batyrkhan Kuatov, MS	Mr. Kuatov has received personal compensation for serving as an employee of CSL Behring. Mr. Kuatov has stock in CSL Behring.
Shicheng Weng, Stat	Mrs. Weng has received personal compensation for serving as an employee of CSL.
Laurence Undreiner	Mrs. Undreiner has received personal compensation for serving as an employee of CSL Behring. Mrs. Undreiner has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Vertex. Mrs. Undreiner has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Krystal Biotech. Mrs. Undreiner has stock in CSL Behring.
Aisara Chansakul, MPH	Mr. Chansakul has nothing to disclose.
Elizabeth Dabrowski, MS	Ms. Dabrowski has nothing to disclose.
Ann Madsen, PhD	Dr. Madsen has received personal compensation for serving as an employee of aetion. Dr. Madsen has stock in Aetion.

��ɫ��

��ɫ��